Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 6/20 | 0.60 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.60 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1357445 | 0.82 | AKR1C3 (0.47) | AKR1C3AKR1C2AKR1C4PTGS1MTNR1A | |
| SCHEMBL29992688 | 0.82 | AKR1C3 (0.47) | AKR1C3AKR1C2AKR1C4PTGS1MTNR1A | |
| SCHEMBL29992656 | 0.82 | AKR1C3 (0.47) | AKR1C3AKR1C2AKR1C4PTGS1MTNR1A | |
| SCHEMBL15902083 | 0.79 | AKR1C3 (0.57) | AKR1C3AKR1C2AKR1C4PTGS1ALDH1A1 | |
| SCHEMBL1778371 | 0.78 | LCK (0.45) | AKR1C3AKR1C2KDM4EALDH1A1HPGD | |
| SCHEMBL21805281 | 0.76 | CDK9 (0.36) | AKR1C3AKR1C2 | |
| SCHEMBL1356595 | 0.76 | ADRB2 (0.56) | MTNR1AKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL2726199 | 0.75 | AKR1C3 (0.66) | AKR1C3AKR1C2AKR1C4PTGS1MTNR1A | |
| SCHEMBL23536738 | 0.75 | KDM4E (0.40) | AKR1C3KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29261926 | 0.74 | HTR6 (0.77) | AKR1C3AKR1C2MTNR1AHTR6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| US-7259154-B2 | Anticancer agents; asthma; rhintis; vision disorders; skin disorders; antiarthritic agents; antiinflammatory agents; antiallergens | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | disclosed |
| US-6897207-B2 | Azaindoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040142947-A1 | Pyrrolopyrimidines | AVENTIS PHARMACEUTICALS, INC. | 2004-07-22 | — | — | US | disclosed |
| EP-1404676-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| WO-2003000695-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | AKR1C3 1503/4885AKR1C2 1390/4885AKR1C4 1500/4885 |
| US-20040142947-A1 | Pyrrolopyrimidines | DPYD, TYMP, PNPO | AKR1C3 399/4885AKR1C2 464/4885AKR1C4 340/4885 |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | MAP3K20, MAP3K12, MAP3K19 | AKR1C3 1785/4885AKR1C2 1920/4885AKR1C4 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.